A month after saying he would resign in the face of sexual harassment allegations, the founder of biotech’s largest and most powerful hedge fund is still on the job, according a federal filing. Sam Isaly’s signature appears at the bottom of a document submitted to the Securities and Exchange Commission on Friday, a filing that lists…